We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here

News

The next steps for biopsies in prostate cancer

Tuesday, August 29, 2017

Jim Hu, M.D., MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medicine, spoke to OncLive about the next steps of biopsies for patients with prostate cancer.

It has become an individual choice of whether a patient should receive a prostate biopsy, explains Hu. This aligns with what other professional organizations are saying. However, it is known that if you compare the use of prostate-specific antigen screening versus monography, it compares quite favorably in terms of the number of men needed to screen to prevent death.